SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For The Quarterly Period Ended March 31, 2004
OR
| ¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission File Number: 0-19171
ICOS CORPORATION
(Exact name of registrant as specified in its charter)
| Delaware | 91-1463450 | |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
22021 - 20th Avenue S.E., Bothell, WA 98021
(Address of principal executive offices) (Zip code)
(425) 485-1900
(Registrants telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes x No ¨
Indicate the number of shares outstanding of each of the issuers classes of Common Stock, as of the latest practicable date.
| Class |
Outstanding at March 31, 2004 | |
| Common Stock, $0.01 par value |
63,337,601 |
FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2004
TABLE OF CONTENTS
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(unaudited)
| Three Months Ended March 31, |
||||||||
| 2004 |
2003 |
|||||||
| Revenue: |
||||||||
| Collaboration revenue from related parties |
$ | 14,067 | $ | 5,348 | ||||
| Licenses of technology |
| 633 | ||||||
| Contract manufacturing |
2,456 | 1,100 | ||||||
| Total revenue |
16,523 | 7,081 | ||||||
| Operating expenses: |
||||||||
| Research and development |
17,254 | 25,142 | ||||||
| Marketing and selling |
9,797 | 921 | ||||||
| Cost of contract manufacturing |
2,513 | 833 | ||||||
| General and administrative |
4,153 | 3,454 | ||||||
| Total operating expenses |
33,717 | 30,350 | ||||||
| Operating loss |
(17,194 | ) | (23,269 | ) | ||||
| Other income (expense): |
||||||||
| Equity in losses of Lilly ICOS |
(69,237 | ) | (21,547 | ) | ||||
| Interest expense |
(1,711 | ) | | |||||
| Interest and other income |
1,839 | 3,712 | ||||||
| Loss before income taxes |
(86,303 | ) | (41,104 | ) | ||||
| Income tax recovery |
| 612 | ||||||
| Net loss |
$ | (86,303 | ) | $ | (40,492 | ) | ||
| Net loss per common share basic and diluted |
$ | (1.36 | ) | $ | (0.65 | ) | ||
| Weighted-average common shares outstanding basic and diluted |
63,237 | 62,174 | ||||||
See accompanying notes to condensed consolidated financial statements.
1
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(unaudited)
| March 31, 2004 |
December 31, 2003 |
|||||||
| ASSETS | ||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 278,187 | $ | 332,039 | ||||
| Investment securities, at market value |
93,221 | 83,049 | ||||||
| Interest receivable |
2,224 | 2,668 | ||||||
| Receivables from affiliates |
18,410 | 17,681 | ||||||
| Note receivable |
| 6,000 | ||||||
| Other |
5,953 | 3,819 | ||||||
| Total current assets |
397,995 | 445,256 | ||||||
| Investment securities, at market value |
61,790 | 51,769 | ||||||
| Property and equipment, net |
18,709 | 18,970 | ||||||
| Deferred financing costs and other |
8,548 | 8,859 | ||||||
| $ | 487,042 | $ | 524,854 | |||||
| LIABILITIES AND STOCKHOLDERS EQUITY | ||||||||
| Current liabilities: |
||||||||
| Payables and accruals |
$ | 17,478 | $ | 17,476 | ||||
| Accrued interest |
1,393 | 2,957 | ||||||
| Due to affiliates |
70,221 | 25,842 | ||||||
| Deferred revenue |
3,049 | 1,000 | ||||||
| Total current liabilities |
92,141 | 47,275 | ||||||
| Convertible subordinated debt |
278,650 | 278,650 | ||||||
| Stockholders equity: |
||||||||
| Common stock |
633 | 630 | ||||||
| Additional paid-in capital |
790,781 | 787,019 | ||||||
| Accumulated other comprehensive income |
613 | 753 | ||||||
| Accumulated deficit |
(675,776 | ) | (589,473 | ) | ||||
| Total stockholders equity |
116,251 | 198,929 | ||||||
| $ | 487,042 | $ | 524,854 | |||||
See accompanying notes to condensed consolidated financial statements.
2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(unaudited)
| Three Months Ended March 31, |
||||||||
| 2004 |
2003 |
|||||||
| Cash flows from operating activities: |
||||||||
| Net loss |
$ | (86,303 | ) | $ | (40,492 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
| Depreciation and amortization |
2,768 | 3,304 | ||||||
| Gain on sale of investment securities, net |
| (1,290 | ) | |||||
| Equity in losses of Lilly ICOS |
69,237 | 21,547 | ||||||
| Revenue collected greater (less) than revenue recognized |
2,049 | (881 | ) | |||||
| Change in operating assets and liabilities: |
||||||||
| Receivables |
(553 | ) | 227 | |||||
| Payables and accruals |
(1,562 | ) | (5,171 | ) | ||||
| Other assets |
(1,891 | ) | (1,385 | ) | ||||
| Other |
119 | 199 | ||||||
| Net cash used in operating activities |
(16,136 | ) | (23,942 | ) | ||||
| Cash flows from investing activities: |
||||||||
| Purchases of investment securities |
(57,277 | ) | (19,167 | ) | ||||
| Maturities of investment securities |
35,960 | 26,365 | ||||||
| Sales of investment securities |
| 88,991 | ||||||
| Acquisitions of property and equipment |
(1,212 | ) | (725 | ) | ||||
| Collection of note receivable arising from sale of partnership interests |
6,000 | | ||||||
| Investments in affiliates |
(24,858 | ) | (22,135 | ) | ||||
| Net cash provided by (used in) investing activities |
(41,387 | ) | 73,329 | |||||
| Cash flows from financing activities: |
||||||||
| Proceeds from stock options |
3,671 | 1,061 | ||||||
| Borrowings under line of credit |
| 2,069 | ||||||
| Net cash provided by financing activities |
3,671 | 3,130 | ||||||
| Net increase (decrease) in cash and cash equivalents |
(53,852 | ) | 52,517 | |||||
| Cash and cash equivalents, beginning of period |
332,039 | 40,450 | ||||||
| Cash and cash equivalents, end of period |
$ | 278,187 | $ | 92,967 | ||||
| Supplemental disclosure of cash flow information: |
||||||||
| Debt forgiveness upon achievement of clinical milestone |
$ | | $ | 3,055 | ||||
| Income tax benefit receivable |
$ | | $ | 612 | ||||
| Interest payments on convertible subordinated debt |
$ | 2,957 | $ | | ||||
See accompanying notes to condensed consolidated financial statements.
3
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In thousands, unless otherwise noted)
(unaudited)
1. Summary of Significant Accounting Policies
The accompanying condensed consolidated financial statements present the results of operations, financial position and cash flows of ICOS Corporation and its wholly-owned subsidiaries, herein collectively referred to as ICOS. All material intercompany transactions and balances between entities consolidated in these financial statements have been eliminated.
The accompanying condensed consolidated financial statements have not been audited. We have condensed or omitted certain information and footnote disclosures normally included in financial statements presented in accordance with accounting principles generally accepted in the United States. We believe the disclosures made are adequate to make the information presented not misleading. However, you should read these condensed consolidated financial statements in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2003.
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Ultimate results could differ from those estimates.
In our opinion, the accompanying condensed consolidated financial statements include all adjustments, consisting only of normal recurring items, necessary to present fairly our financial position as of March 31, 2004 and December 31, 2003, and our results of operations and cash flows for the three months ended March 31, 2004 and 2003. Interim results are not necessarily indicative of results for a full year.
Stock Based Compensation
We apply the provisions of Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock Issued to Employees, and related interpretations in accounting for our employee stock option grants. Accordingly, we do not recognize compensation expense for options granted to employees with an exercise price equal to or in excess of the fair value of the underlying common shares at the date of grant. We recognize compensation expense for restricted stock grants over the applicable vesting period.
4
Had we determined compensation cost based on the fair value of our stock options on the grant date under Statement of Financial Accounting Standards No. 123, Accounting for Stock Based Compensation, our net loss and net loss per share would have been the following pro forma amounts:
| Three Months Ended March 31, |
||||||||
| 2004 |
2003 |
|||||||
| Net loss: |
||||||||
| As reported |
$ | (86,303 | ) | $ | (40,492 | ) | ||
| Add: Stock based employee compensation expense included in reported net loss |
69 | 69 | ||||||
| Deduct: Stock based employee compensation expense determined under fair value based method for all awards |
(9,041 | ) | (11,564 | ) | ||||
| Pro forma |
$ | (95,275 | ) | $ | (51,987 | ) | ||
| Net loss per sharebasic and diluted: |
||||||||
| As reported |
$ | (1.36 | ) | $ | (0.65 | ) | ||
| Pro forma |
$ | (1.51 | ) | $ | (0.84 | ) | ||
The estimated per share weighted-average grant date fair value of stock options awarded during the three months ended March 31, 2004 and 2003, was $27.67 and $13.79, respectively. Amounts were determined using the Black-Scholes option pricing model based on the following assumptions:
| Three Months Ended March 31, |
||||||
| 2004 |
2003 |
|||||
| Expected dividend yield |
0.0 | % | 0.0 | % | ||
| Risk-free interest rate |
3.4 | % | 3.3 | % | ||
| Expected volatility |
68.1 | % | 67.9 | % | ||
| Expected life in years |
6.6 | 6.4 | ||||
In March 2004, the Financial Accounting Standards Board issued an Exposure Draft of a proposed Statement of Financial Accounting Standards entitled Share-Based Payment. This proposed Statement addresses accounting for stock based compensation and would result in stock based compensation costs, including options, being recognized as an expense in the financial statements. The proposed Statement would eliminate the ability to account for stock based compensation transactions using APB Opinion No. 25, and generally would require that such transactions be accounted for using a fair value based method. If approved, the proposed statement would be applied to public entities, prospectively, for fiscal years beginning after December 15, 2004.
2. Revenue from Collaborations and Licenses of Technology
The following tables summarize our revenue from collaborations with related parties and licenses of technology for the three months ended March 31, 2004 and 2003.
| Three Months Ended March 31, | ||||||
| 2004 |
2003 | |||||
| Collaboration revenue from related parties: |
||||||
| Lilly ICOS LLC (Lilly ICOS) |
$ | 14,067 | $ | 2,053 | ||
| Sunc | ||||||